Multiple myeloma, a type of cancer that affects plasma cells in bone marrow, has seen significant advancements in research. Scientists are delving into targeted therapies, such as proteasome inhibitors and immunomodulatory drugs, which disrupt cancer cell growth and enhance the immune system's ability to fight the disease. Additionally, monoclonal antibodies are being developed to specifically target myeloma cells, minimizing harm to healthy cells. Novel treatment approaches like CAR-T cell therapy hold promise, harnessing the body's immune cells to seek and destroy cancerous ones. Moreover, genetic profiling allows for personalized treatment strategies, optimizing outcomes for individual patients. With these multifaceted approaches, cancer researchers are making remarkable strides in improving survival rates and enhancing the quality of life for those battling multiple myeloma.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China